Elanco Welcomes Dr. Stacey Ma to Board, Enhancing Expertise

Elanco Animal Health Strengthens Board with Dr. Stacey Ma

Elanco Animal Health Incorporated (NYSE: ELAN) is pleased to announce the appointment of Dr. Stacey Ma to its Board of Directors. Dr. Ma is recognized for her deep knowledge and expertise in manufacturing and innovation, enhancing the capabilities of the Board immediately.

Background and Expertise of Dr. Stacey Ma

Dr. Ma joins Elanco with a wealth of experience in biopharmaceutical development and manufacturing. Currently, she serves as the Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc. Her role encompasses product and portfolio strategy, overseeing technical development, supply chain, quality assurance, CMC regulatory affairs, and manufacturing operations for a diverse range of therapeutic products.

Leadership Experience

Prior to her position at Gilead, Dr. Ma held various leadership roles at Sana Biotechnology, Inc. and Genentech/Roche. Her impressive career is marked by her role as Global Head of Pharma Technical Innovation at Genentech, where she drove significant advancements in manufacturing science and technology.

Statements from Elanco Leadership

Lawrence Kurzius, Chairman of the Elanco Board, expressed, "We are thrilled to have Stacey join us. Her rich understanding of product development and chemistry, along with her expertise in manufacturing and controls, will be invaluable as we continue to enhance our innovation capabilities."

Dr. Ma's Commitment to Animal Health

In her own words, Dr. Ma stated, "Joining Elanco's Board is an honor. I am passionate about technical excellence and innovation in the life sciences sector, and I am eager to contribute to Elanco's mission of enhancing the health and well-being of animals."

Significant Contributions of Dr. Ma

Dr. Ma's contributions extend beyond Elanco. She has played a vital role in the scientific community, co-chairing numerous international scientific conferences. Her leadership as an Associate Director of the Board of the Council of Science and Technology (CASSS) illustrates her commitment to advancing medical and biological engineering.

Acknowledgment and Recognition

Her peers recognized her as one of the "Top 20 Women Leaders in Biopharma R&D" by Endpoints News in 2020, reflecting her significant impact on the industry.

Future endeavors with Elanco

Jeff Simmons, CEO of Elanco Animal Health, stated, "Stacey's guidance will be crucial as our Innovation, Portfolio, and Productivity strategies evolve. Her experience in drug development will assist in transitioning our significant products from research into manufacturing, ensuring we deliver high-impact innovations consistently."

Educational Background

Dr. Ma holds both master's and doctorate degrees in chemical engineering from Yale University, along with a bachelor's degree in chemical engineering from the University of Minnesota. Her educational background provides a solid foundation for her professional accomplishments.

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health. The company dedicates itself to developing innovative products and services aimed at preventing and treating diseases in both farm animals and pets. With nearly seventy years of experience, Elanco focuses on enhancing the health and well-being of animals while fostering value for farmers, pet owners, veterinarians, and society.

Aligned with its vision of improving lives through food and companionship, Elanco operates under its sustainability pillars to advance animal, human, and environmental health. For more details, visit www.elanco.com.

Investor contacts at Elanco include Kathryn Grissom at +1.317.273.9284 and media inquiries can be directed to Colleen Parr Dekker at +1.317.989.7011.

Frequently Asked Questions

1. Who is Dr. Stacey Ma?

Dr. Stacey Ma is the newly appointed member of Elanco's Board of Directors, known for her extensive background in biopharmaceutical development and manufacturing.

2. What role does Dr. Ma hold at Gilead Sciences?

She serves as the Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, overseeing various technical and operational aspects.

3. What is Elanco's mission?

Elanco's mission is to enhance the health and well-being of animals, benefiting farmers, pet owners, and society as a whole.

4. How long has Elanco been in the animal health industry?

Elanco has nearly seventy years of experience in the animal health sector, committed to innovation and excellence.

5. Where can I find more information about Elanco?

More information about Elanco can be found on their official website at www.elanco.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.